Cargando…

Synergistic effects of sitagliptin and losartan against fipronil-induced hepatotoxicity in rats

BACKGROUND AND AIM: Fipronil (FPN) is a potent pesticide that is heavily used around the world in agriculture. However, its irrational use could potentially have deleterious effects on animals and humans. The present study aimed to investigate the ability of sitagliptin (Sit) and losartan (LOS), whe...

Descripción completa

Detalles Bibliográficos
Autores principales: Elazab, Sara T., Samir, Omar, Abass, Marwa E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Veterinary World 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8404120/
https://www.ncbi.nlm.nih.gov/pubmed/34475715
http://dx.doi.org/10.14202/vetworld.2021.1901-1907
_version_ 1783746108520923136
author Elazab, Sara T.
Samir, Omar
Abass, Marwa E.
author_facet Elazab, Sara T.
Samir, Omar
Abass, Marwa E.
author_sort Elazab, Sara T.
collection PubMed
description BACKGROUND AND AIM: Fipronil (FPN) is a potent pesticide that is heavily used around the world in agriculture. However, its irrational use could potentially have deleterious effects on animals and humans. The present study aimed to investigate the ability of sitagliptin (Sit) and losartan (LOS), when used both individually or concurrently, to guard rat liver against the acute hepatotoxicity caused by FPN. MATERIALS AND METHODS: Forty-two adult male Wistar rats were equally divided into seven groups (6/group). Group I (control) received normal saline (0.5 mL/rat, vehicle for all treatments) by gavage once daily for 10 days. Group II received oral Sit (10 mg/kg body weight [BW]) daily for 10 days and Group III received oral LOS (5 mg/kg BW) daily for 10 days. Group IV received oral FPN (19.4 mg/kg BW; 1/5 of the oral LD(50)) for the past 5 days of the study. Groups V and VI received oral Sit (10 mg/kg BW) and LOS (5 mg/kg BW) daily, respectively, 5 days prior and 5 days during FPN administration (19.4 mg/kg BW). Group VII received oral Sit (10 mg/kg BW) and LOS (5 mg/kg BW) for 10 days with daily FPN during the past 5 days. After the end of the treatment period, the rats were humanely sacrificed and blood and liver tissue samples were collected for biochemical analysis and histopathological and immunohistochemical investigations. RESULTS: FPN administration resulted in elevated alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase serum concentrations as well as increased malondialdehyde levels and reduced catalase, superoxide dismutase, glutathione peroxidase, and glutathione activity. The histopathological investigation showed disorganization of the hepatic cords and focal necrosis of the hepatocytes in FPN-intoxicated rats. Furthermore, the immunohistochemical examination showed that hepatic caspase-3 was overexpressed in the FPN-treated rats. The administration of Sit and LOS before and alongside FPN markedly mitigated the alterations caused by FPN and the hepatoprotective effects were more prominent in the combination group. CONCLUSION: Sit and LOS, both individually or in combination, confers considerable hepatoprotection against FPN-induced hepatotoxicity.
format Online
Article
Text
id pubmed-8404120
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Veterinary World
record_format MEDLINE/PubMed
spelling pubmed-84041202021-09-01 Synergistic effects of sitagliptin and losartan against fipronil-induced hepatotoxicity in rats Elazab, Sara T. Samir, Omar Abass, Marwa E. Vet World Research Article BACKGROUND AND AIM: Fipronil (FPN) is a potent pesticide that is heavily used around the world in agriculture. However, its irrational use could potentially have deleterious effects on animals and humans. The present study aimed to investigate the ability of sitagliptin (Sit) and losartan (LOS), when used both individually or concurrently, to guard rat liver against the acute hepatotoxicity caused by FPN. MATERIALS AND METHODS: Forty-two adult male Wistar rats were equally divided into seven groups (6/group). Group I (control) received normal saline (0.5 mL/rat, vehicle for all treatments) by gavage once daily for 10 days. Group II received oral Sit (10 mg/kg body weight [BW]) daily for 10 days and Group III received oral LOS (5 mg/kg BW) daily for 10 days. Group IV received oral FPN (19.4 mg/kg BW; 1/5 of the oral LD(50)) for the past 5 days of the study. Groups V and VI received oral Sit (10 mg/kg BW) and LOS (5 mg/kg BW) daily, respectively, 5 days prior and 5 days during FPN administration (19.4 mg/kg BW). Group VII received oral Sit (10 mg/kg BW) and LOS (5 mg/kg BW) for 10 days with daily FPN during the past 5 days. After the end of the treatment period, the rats were humanely sacrificed and blood and liver tissue samples were collected for biochemical analysis and histopathological and immunohistochemical investigations. RESULTS: FPN administration resulted in elevated alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase serum concentrations as well as increased malondialdehyde levels and reduced catalase, superoxide dismutase, glutathione peroxidase, and glutathione activity. The histopathological investigation showed disorganization of the hepatic cords and focal necrosis of the hepatocytes in FPN-intoxicated rats. Furthermore, the immunohistochemical examination showed that hepatic caspase-3 was overexpressed in the FPN-treated rats. The administration of Sit and LOS before and alongside FPN markedly mitigated the alterations caused by FPN and the hepatoprotective effects were more prominent in the combination group. CONCLUSION: Sit and LOS, both individually or in combination, confers considerable hepatoprotection against FPN-induced hepatotoxicity. Veterinary World 2021-07 2021-07-25 /pmc/articles/PMC8404120/ /pubmed/34475715 http://dx.doi.org/10.14202/vetworld.2021.1901-1907 Text en Copyright: © Elazab, et al. https://creativecommons.org/licenses/by/4.0/Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Elazab, Sara T.
Samir, Omar
Abass, Marwa E.
Synergistic effects of sitagliptin and losartan against fipronil-induced hepatotoxicity in rats
title Synergistic effects of sitagliptin and losartan against fipronil-induced hepatotoxicity in rats
title_full Synergistic effects of sitagliptin and losartan against fipronil-induced hepatotoxicity in rats
title_fullStr Synergistic effects of sitagliptin and losartan against fipronil-induced hepatotoxicity in rats
title_full_unstemmed Synergistic effects of sitagliptin and losartan against fipronil-induced hepatotoxicity in rats
title_short Synergistic effects of sitagliptin and losartan against fipronil-induced hepatotoxicity in rats
title_sort synergistic effects of sitagliptin and losartan against fipronil-induced hepatotoxicity in rats
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8404120/
https://www.ncbi.nlm.nih.gov/pubmed/34475715
http://dx.doi.org/10.14202/vetworld.2021.1901-1907
work_keys_str_mv AT elazabsarat synergisticeffectsofsitagliptinandlosartanagainstfipronilinducedhepatotoxicityinrats
AT samiromar synergisticeffectsofsitagliptinandlosartanagainstfipronilinducedhepatotoxicityinrats
AT abassmarwae synergisticeffectsofsitagliptinandlosartanagainstfipronilinducedhepatotoxicityinrats